First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial-Reference-Cited by-同舟云学术

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial

Published:2021-11 Issue: Volume:157 Page:268-277
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Morscher Raphael J.,Brard Caroline^ORCID,Berlanga Pablo^ORCID,Marshall Lynley V.^ORCID,André Nicolas^ORCID,Rubino Jonathan^ORCID,Aerts Isabelle,De Carli Emilie^ORCID,Corradini Nadège,Nebchi Souad,Paoletti Xavier,Mortimer Peter,Lacroix Ludovic,Pierron Gaelle,Schleiermacher Gudrun^ORCID,Vassal Gilles,Geoerger Birgit^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study;Gatta;Lancet Oncol,2014

2. Target and agent prioritization for the children's oncology group-national cancer Institute pediatric MATCH trial;Allen;J Natl Cancer Inst,2017

3. Molecular screening for cancer treatment optimization (MOSCATO-01) in pediatric patients: a single-institutional prospective molecular stratification trial;Harttrampf;Clin Canc Res: Off J Am Assoc Canc Res,2017

4. Next-generation personalised medicine for high-risk paediatric cancer patients - the INFORM pilot study;Worst;Eur J Canc,2016

5. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies;Barrett;Paediatr Drugs,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection and validation of reference genes for RT-qPCR normalization in dormant cancer cells;2024-09-13

2. Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART;European Journal of Cancer;2024-09

3. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer;European Journal of Cancer;2024-08

4. MLIP and Its Potential Influence on Key Oncogenic Pathways;Cells;2024-06-26

5. Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy;eBioMedicine;2024-05